In other studies, while using gene expression screening in mammary tumours, it was indicated that ER-positive breast tumours with poor response to endocrine therapy tend to have lower ERα expression and high levels of proliferation-associated genes [32,34–36]. This evidence concerns the gene ESR1 and breast neoplasm.